Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jul;37(4):220–226. doi: 10.1007/BF01518514

Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C

Shinya Arinaga 1, Nobuya Karimine 1, Masashi Adachi 1, Hiroshi Inoue 1, Shigeru Nanbara 1, Tsukasa Asoh 1, Hiroaki Ueo 1, Tsuyoshi Akiyoshi 1,✉
PMCID: PMC11038193  PMID: 8348560

Abstract

We previously found that the ability of peripheral blood mononuclear cells (PBM) of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C administration. On the basis of the clinical finding, we designed a treatment regimen comprised of 12 mg/m2 mitomycin C i. v. on day 1 and 700 U/m2 recombinant interleukin-2 (IL-2) i.v. every 12 h from day 4 through day 8. Of 25 patients with advanced carcinoma, 9 had a partial response and 3 had a minor response. Cytotoxic cell function, including natural killer activity, lymphokine-activated killer (LAK) activity, and the ability to generate LAK cells, and lymphocyte subsets in PBM was measured 1 day before and after either the first or second course of this therapy. The relationship between these parameters and the clinical antitumor response to this treatment was examined. Although the cytotoxic activities were significantly augmented after either the first or second treatment course, no positive correlation was observed between the changes in these cytotoxic activities and the clinical response to this therapy, when patients who either showed a partial response or whose disease remission was partial or minor were defined as responders. Further, phenotypic analysis showed a significant increase in CD2+, CD3+ CD4+ and CD4+Leu8− cells after the firs course, and CD25+ cells after either the first or second course of this treatment. The precentages of CD2+ and CD25+ cells were significantly elevated only in responders but not in nonresponders, suggesting the increase in these subsets was related to clinical response.

Key words: Cytotoxic activity, Phenotypic analysis, Peripheral blood mononuclear cell, Interleukin-2, Mitomycin C, Clinical response

References

  • 1.Akiyoshi T, Arinaga S, Karimine N, Inoue H, Abe R, Takamuku K, Watanabe D, Nagamatsu M, Matsuoka H, Ueo H. Effect of recombinant interleukin 2 in combination with mitomycin C or adriamycin on advanced cancer. Proc. Am Assoc Cancer Res. 1990;31:273. doi: 10.1007/BF02470676. [DOI] [PubMed] [Google Scholar]
  • 2.Akiyoshi T, Arinaga S, Nanbara S, Karimine N, Inoue H, Takamuku K, Abe R, Watanabe D, Nagamatsu M, Matsuoka H, Ueo H. The effect of interleukin 2 in combination with mitomycin C on advanced cancer. Jpn. J Surg. 1990;20:365. doi: 10.1007/BF02470676. [DOI] [PubMed] [Google Scholar]
  • 3.Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H, Akiyoshi T. Correlation of eosinophila with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immunother. 1992;35:246. doi: 10.1007/BF01789330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Blay J-Y, Favrot MC, Negrier S, Cambaret V, Chouaib S, Mercatellow A, Maemmerlen P, Franks CR, Philip T. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res. 1990;50:2371. [PubMed] [Google Scholar]
  • 5.Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol. 1991;9:2110. doi: 10.1200/JCO.1991.9.12.2110. [DOI] [PubMed] [Google Scholar]
  • 6.Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlaton of response with T-cell infiltration and HLA-DR expression. Am J Pathol. 1987;129:208. [PMC free article] [PubMed] [Google Scholar]
  • 7.Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen II, Bhoopatam NB, Jassak PF, Cahill MA, Canzoneri CL, Fisher RI. A phase I clinical trial of recombinant interleukin 2 by periodic 24-hour intravenous infusions. J Clin Oncol. 1989;7:276. doi: 10.1200/JCO.1989.7.2.276. [DOI] [PubMed] [Google Scholar]
  • 8.Eberlein TJ, Rodrick ML, Massaro AF, Jung S-E, Mannick JA, Schoof DD. Imunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Immunol Immunother. 1989;30:145. doi: 10.1007/BF01669422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod. 1990;9:167. [PubMed] [Google Scholar]
  • 10.Gambacorti-Passerini C, Radrizzani M, Marolda R, Belli G. In vivo activation of lymphocytes in melanoma patients receiving esclating doses of recombinant interleukin 2. Int J Cancer. 1988;41:700. doi: 10.1002/ijc.2910410511. [DOI] [PubMed] [Google Scholar]
  • 11.Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988;48:5864. [PubMed] [Google Scholar]
  • 12.Ghosh AK, Dazzi H, Thatcher N, Moore M. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer. 1989;43:410. doi: 10.1002/ijc.2910430311. [DOI] [PubMed] [Google Scholar]
  • 13.Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, Sondel PM. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. Cancer Res. 1989;49:6832. [PubMed] [Google Scholar]
  • 14.Hanninen EL, Korfer A, Hadam M, Schneekloth C, Dallmann I, Manzel T, Kirchner H, Poliwoda H, Atzpodien J. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res. 1991;50:6312. [PubMed] [Google Scholar]
  • 15.Hermann GG, Geertsen PF, Masse H, Zeuthen J. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin 2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother. 1991;34:111. doi: 10.1007/BF01741344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hermann GG, Geertsen PF, Maase H, Steven K, Andersen C, Hald T, Zeuthen J. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res. 1992;52:726. [PubMed] [Google Scholar]
  • 17.Hinuma S, Onda H, Naruo K, Ichimori Y, Koyama M, Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes inXenopus oocytes. Biochem Biophys Res Commun. 1982;109:363. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  • 18.Kasid A, Director EP, Rosenberg SA. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol. 1989;143:736. [PubMed] [Google Scholar]
  • 19.Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol. 1990;8:460. doi: 10.1200/JCO.1990.8.3.460. [DOI] [PubMed] [Google Scholar]
  • 20.Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987;47:2188. [PubMed] [Google Scholar]
  • 21.Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol. 1988;6:409. doi: 10.1200/JCO.1988.6.3.409. [DOI] [PubMed] [Google Scholar]
  • 22.Mule JJ, Yang JC, Lafreniere S, Shu S, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by systemic administration of high-dose recombinant interleukin-2. J Immunol. 1987;139:285. [PubMed] [Google Scholar]
  • 23.Nanbara S, Arinaga S, Akiyshi T. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Cancer Immunol Immunother. 1989;29:237. doi: 10.1007/BF00199210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Park KGH, Heys DS, Murray JB, Hays PD, Ashoby JA, Franks CR. Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity. Cancer Immunol Immunother. 1992;35:53. doi: 10.1007/BF01741055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Peace DJ, Cheever MA. Toxicity and therapeutic efficacy of high-dose interleukin-2. J Exp Med. 1989;169:161. doi: 10.1084/jem.169.1.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined interleukin-2 and LAK cell therapy. J Clin Oncol. 1987;5:1933. doi: 10.1200/JCO.1987.5.12.1933. [DOI] [PubMed] [Google Scholar]
  • 27.Rosenberg SA, Lotze MT, Muul JM, Chang AE, Avis EP, Leitman S, Linchan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White MS. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose IL 2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 28.Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 1989;49:7086. [PubMed] [Google Scholar]
  • 29.Taguchi T, Kimoto Y. Clinical application of biological response modifiers: interleukin 2. Saishin-Igaku. 1987;42:325. [Google Scholar]
  • 30.Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol. 1988;6:669. doi: 10.1200/JCO.1988.6.4.669. [DOI] [PubMed] [Google Scholar]
  • 31.Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clarks JW. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990;50:185. [PubMed] [Google Scholar]
  • 32.Weidmann E, Bergmann L, Hechler P, Mitrou PS. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. Cancer Immunol Immunother. 1991;33:398. doi: 10.1007/BF01741601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.West WH, Tanner KW, Yanelli JR, Marshall GD, Orr DW, Thurmann GB, Oldham RT. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:398. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  • 34.Yamaguchi Y, Suda T, Shiozaki H, Miura Y, Hitoshi Y, Tominaga A, Takatsu K, Kasahara T. Role of IL-5 in IL-2-induced eosinophilia: in vivo and in vitro expression of IL-5 mRNA by IL-2. J Immunol. 1990;145:873. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES